Select Language
CXADR
CXADR Overview
| English Name | Calcium sensing receptor | Approved Drugs | 6 |
| Drugs in Clinical Trials | 5 | Target Synonym | Parathyroid cell calcium-sensing receptor 1，FHH，FIH，HHC，Receptors， Calcium-Sensing，Extracellular calcium-sensing receptor，hCasR，GPRC2A，Calcium Sensing Receptor，Parathyroid Ca(2+)-Sensing Receptor 1，Severe Neonatal Hyperparathyroidism，Calcium-Sensing Receptor，HYPOC1，NSHPT，PCaR1，EIG8，HHC1，CaSR，CAR，Hypocalciuric Hypercalcemia 1 |
| Highest Development Stage | Approved | ||
| English Name | Calcium sensing receptor |
| Target Synonym | Parathyroid cell calcium-sensing receptor 1，FHH，FIH，HHC，Receptors， Calcium-Sensing，Extracellular calcium-sensing receptor，hCasR，GPRC2A，Calcium Sensing Receptor，Parathyroid Ca(2+)-Sensing Receptor 1，Severe Neonatal Hyperparathyroidism，Calcium-Sensing Receptor，HYPOC1，NSHPT，PCaR1，EIG8，HHC1，CaSR，CAR，Hypocalciuric Hypercalcemia 1 |
| Approved Drugs | 6 |
| Drugs in Clinical Trials | 5 |
| Highest Development Stage | Approved |
CXADR Product List
- Product Category
Protein (1)
- Product Status
Launched (1)
- Species
Human (1)
- Tag
His Tag (1)
- Conjugate
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
CXR-H5222 |  Human | HEK293 | Human CXADR / CAR Protein, His Tag |  |  |  Add to Cart |
Total: 1
- 1
CXADR Background
Coxsackie virus and adenovirus receptor (CXADR) is also known as CAR, is a type I transmembrane glycoprotein for group B coxsackie viruses and subgroup C adenoviruses, and belongs to the CTX family of the Ig superfamily. CAR is strongly expressed in the developing central nervous system. It functions as a homophilic and also as a heterophilic cell adhesion molecule through its interactions with extracellular matrix glycoproteins such as: fibronectin, agrin, laminin-1 and tenascin-R. Human CXADR protein contains a signal sequence, a extracellular domain (ECD) with a V type (D1) and a C2 type (D2) Iglike domain, a transmembrane segment and a intracellular domain. D1 is thought to be responsible for homodimer formation in trans within tight junctions, and is necessary and sufficient for adenovirus binding. Variants of CXADR are attached to the cell membrane by a GPI- anchor.
CXADR Synonyms
CXADR,CAR,CAR4,6,HCAR
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Encaleret sulfate | MK-5442; JTT-305; BBP-305; CLTX-305 | Phase 3 Clinical | Japan Tobacco (Hong Kong) Ltd | Osteoporosis; Hypocalcemia; Osteoporosis, Postmenopausal; Hypoparathyroidism | Details |
| SHR-6508 | SHR-6508 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Hyperparathyroidism, Secondary; Kidney Diseases; Renal Insufficiency, Chronic; Hyperparathyroidism | Details |
| LNP-1892 | LNP-1892 | Phase 2 Clinical | Lupin Ltd | Hyperparathyroidism | Details |
| DS-9194b | DS-9194b | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Osteoporosis | Details |
| RT-102(Rani) | RT-102 | Phase 1 Clinical | Rani Therapeutics Holdings Inc | Osteoporosis | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Upacicalcet | SK-1403; AJT-240 | Approved | Ajinomoto Co Inc | ウパシタ, Upasita | Japan | Hyperparathyroidism, Secondary | Sanwa Kagaku Kenkyusho Co Ltd | 2021-06-23 | Hyperparathyroidism, Secondary | Details |
| Parathyroid hormone (Shire) | SHP-634; ALX-111; 423562; NPSP-795; rhPTH (1-84); SHP-635; rhPTH-1-84; PTH (1-84); SB-423562; PTH 1-84; NPSP-558 | Approved | Shire | Natpara, Preotact, Natpar | United States | Hypoparathyroidism | Nps Pharmaceuticals, Inc | 2006-04-24 | Osteoporosis; Bone Diseases, Endocrine; Osteoporosis, Postmenopausal; Hypocalcemia; Hypoparathyroidism; Hyperparathyroidism; Plaque psoriasis | Details |
| Cinacalcet Hydrochloride | AMG-073.HCl; NPS-1493; AMG-073; KRN-1493 | Approved | Amgen Inc | Parareg, Sensipar, Mimpara, Regpara, 盖平, Sensipar/Mimpara | United States | Hypercalcemia; Hyperparathyroidism, Secondary | Amgen Inc | 2004-03-08 | Hyperparathyroidism, Secondary; Rejection of renal transplantation; Hypophosphatemia; Edema, Cardiac; Nephrosis; Renal Insufficiency; Parathyroid Neoplasms; Hypercalcemia; Kidney Diseases; Hyperparathyroidism, Primary; Prostatic Neoplasms; Osteomalacia; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder | Details |
| Etelcalcetide Hydrochloride | ONO-5163; KAI-4169; AMG-416; KAI-4169-HCl | Approved | Amgen Inc | Parsabiv | EU | Hyperparathyroidism, Secondary | Amgen Europe Bv | 2016-11-11 | Hyperparathyroidism, Secondary; Edema, Cardiac; Renal Insufficiency, Chronic; Kidney Failure, Chronic | Details |
| Strontium Ranelate | S-12911; S-12911-2; FK-481 | Approved | Laboratoires Servier | Osseor, Protos, Protelos, 欧思美 | Mainland China | Osteoporosis, Postmenopausal | Les Laboratoires Servier | 2004-09-20 | Osteoporosis, Postmenopausal | Details |
| Evocalcet | KHK-7580; MT-4580 | Approved | Mitsubishi Tanabe Pharma Corp | Orkedia | Japan | Hyperparathyroidism, Secondary | Kyowa Hakko Kirin Co Ltd | 2018-03-23 | Hyperparathyroidism, Secondary; Parathyroid Neoplasms; Hyperparathyroidism, Primary; Hyperparathyroidism | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland